Results 31 to 40 of about 530,197 (354)
European Urology Open Science, 2022 Background: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that ...
Naheema S. Gordon +9 more
doaj
The prognostic significance of DAPK1 in bladder cancer. [PDF]
PLoS ONE, 2017 Bladder cancer is one of the leading causes of cancer-related death in men, however, there was only limited effective treatment for invasive bladder cancer.
Jian-Yun Xie +9 more
doaj +1 more source
Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center [PDF]
, 2019 Objectives: To evaluate accuracy and inter-observer variability using Vesical Imaging-Reporting and Data System (VI-RADS) for discrimination between non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).
Barchetti, Giovanni +11 more
core +1 more source
TGF-β1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells
Journal of Translational Medicine, 2023 Background Bladder cancer is one of the most common malignant tumors of the urinary system and is associated with a poor prognosis once invasion and distant metastases occur.
Qinrong Ping +21 more
doaj +1 more source
Genetic and Epigenetic Alterations in Bladder Cancer [PDF]
International Neurourology Journal, 2016 Bladder cancer is one of the most common cancers worldwide, with a high rate of recurrence and poor outcomes as a result of relapse. Bladder cancer patients require lifelong invasive monitoring and treatment, making bladder cancer one of the most ...
Hong-Tao Li +3 more
doaj +1 more source
The Landscape of Long Non-Coding RNA Dysregulation and Clinical Relevance in Muscle Invasive Bladder Urothelial Carcinoma. [PDF]
, 2019 Bladder cancer is one of the most common cancers in the United States, but few advancements in treatment options have occurred in the past few decades.
Chang, Eric Y +7 more
core +1 more source
European Urology Open Science, 2023 Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been correlated with response.
Evangelia Vlachou +6 more
doaj
Frontiers in Immunology, 2023 With the rapidly increasing incidence of bladder cancer in China and worldwide, great efforts have been made to understand the detailed mechanism of bladder cancer tumorigenesis.
Maoyu Wang +5 more
doaj +1 more source
Schistosomiasis and Urinary Bladder Cancer in North Western Tanzania: A Retrospective Review of 185 Patients. [PDF]
, 2013 Worldwide, cancers of the urinary bladder are well known to be associated with environmental chemical carcinogens such as smoking and occupational exposure to polycyclic aromatic hydrocarbons.
A Yosry +31 more
core +1 more source
The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer
Cell Death and Disease, 2021 Bladder cancer is one of the most lethal cancers in the world. Despite the continuous development of medical technologies and therapeutic strategies, the overall survival rate of bladder cancer has not changed significantly.
Lu Yi +6 more
doaj +1 more source